Stephanie Westington Insider Trade for 594 Shares of FNCB Bancorp, Inc. (FNCB); 3 Analysts Bullish Bio-Rad Laboratories, Inc. (BIO)

May 18, 2018 - By Matthew Harris

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Among 5 analysts covering Bio-Rad Laboratories (NYSE:BIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bio-Rad Laboratories had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, April 12 by Jefferies. On Friday, February 16 the stock rating was downgraded by CL King to “Neutral”. Jefferies maintained the shares of BIO in report on Thursday, June 8 with “Buy” rating. On Wednesday, September 27 the stock rating was maintained by Jefferies with “Buy”. Wells Fargo maintained the shares of BIO in report on Tuesday, March 20 with “Buy” rating. The firm earned “Buy” rating on Friday, April 28 by Jefferies. The rating was maintained by Jefferies with “Buy” on Thursday, July 13. The firm has “Outperform” rating by Wells Fargo given on Wednesday, February 28. Jefferies maintained it with “Buy” rating and $285.0 target in Friday, October 20 report. Jefferies maintained it with “Buy” rating and $300.0 target in Friday, November 3 report. See Bio-Rad Laboratories, Inc. (NYSE:BIO) latest ratings:

20/03/2018 Broker: Wells Fargo Rating: Buy New Target: $290.0 Maintain
28/02/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $290 New Target: $280 Maintain
16/02/2018 Broker: CL King Old Rating: Buy New Rating: Neutral Downgrade
16/02/2018 Broker: C.L. King Rating: Hold Downgrade
29/11/2017 Broker: Wells Fargo Rating: Buy New Target: $290.0 Maintain

Since December 14, 2017, it had 0 insider buys, and 1 insider sale for $1.24 million activity. On Thursday, December 14 TSINGOS CHRISTINE A sold $1.24M worth of Bio-Rad Laboratories, Inc. (NYSE:BIO) or 4,980 shares.

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: which released: “Research Report Identifies Bio-Rad Laboratories, Bright Horizons Family Solutions, Corbus Pharmaceuticals …” on May 18, 2018, also with their article: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” published on May 17, 2018, published: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: and their article: “Bio-Rad Reports First Quarter 2018 Financial Results” published on May 08, 2018 as well as‘s news article titled: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” with publication date: May 11, 2018.

The stock decreased 1.68% or $4.89 during the last trading session, reaching $286.82. About 391,342 shares traded or 139.06% up from the average. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since May 18, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.35, from 0.78 in 2017Q3. It is positive, as 23 investors sold Bio-Rad Laboratories, Inc. shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported. Acadian Asset Mgmt Lc reported 832,546 shares. Arrowstreet Partnership owns 8,800 shares for 0.01% of their portfolio. 4,400 are owned by Eulav Asset Mgmt. Principal Group, a Iowa-based fund reported 86,209 shares. Neuberger Berman Group Limited Liability Company owns 0.04% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 131,273 shares. Moreover, Renaissance Technology Ltd Llc has 0.08% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO). Invesco reported 57,544 shares stake. Metropolitan Life Insurance Com has 5,814 shares. Brinker Cap reported 0.04% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Epoch Investment Ptnrs holds 0.16% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 197,570 shares. 2,268 are held by Riverhead Mngmt Limited Liability Company. Aperio Gru Limited Com owns 0.02% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 18,892 shares. Bluemountain Capital Mgmt Limited Liability Co has invested 0.05% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Hermes Invest Mngmt Ltd accumulated 0.66% or 191,657 shares. Earnest Prtnrs Ltd owns 0.25% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 109,307 shares.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $8.50 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 75.08 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

The stock decreased 2.01% or $0.19 during the last trading session, reaching $9.28. About 600 shares traded. FNCB Bancorp, Inc. (NASDAQ:FNCB) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

More news for FNCB Bancorp, Inc. (NASDAQ:FNCB) were recently published by:, which released: “FNCB Bancorp, Inc. Increases Second Quarter Dividend 33%” on April 25, 2018.‘s article titled: “FNCB Bancorp, Inc. Announces 1st Quarter 2018 Earnings” and published on April 20, 2018 is yet another important article.

Stephanie Westington – a famous insider in Fncb Bancorp Inc who’s currently a SVP/CONTROLLER — unloaded 594 shares of Fncb Bancorp Inc, with market value of about about USD 5,425 at average stock price per share of USD 9.1. And, It’s sure Stephanie’s stocks unloading isn’t going to stay unseen as she right now is having rights to 10,107 shares – ( 0.06% of Fncb Bancorp Inc’s Market Cap ).

FNCB Bancorp, Inc. operates as the holding firm for FNCB Bank that provides retail and commercial banking services to individuals and businesses in Northeastern Pennsylvania. The company has market cap of $155.62 million. It offers checking, savings, and certificate of deposit products. It has a 1031.11 P/E ratio. The firm also provides one- to four-family residential mortgage loans; construction, land acquisition, and development loans; commercial real estate loans; commercial and industrial loans; consumer loans, such as secured and unsecured installment loans, lines of credit, overdraft protection loans, auto loans, home equity loans, and lines of credit; and state and political subdivision loans.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: